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Pharmacy costs of specialty medications for plaque psoriasis in the United States
To the Editor: The 2013 American Academy of Dermatology report on the national burden of skin disease estimated that $15.6 billion was spent on prescription drugs and vaccines for skin disease, with specialty drugs (including biologic and newer oral agents for plaque psoriasis) accounting for 15% of that cost. 1 Drugs used in dermatology represent 3 of the 5 most expensive drugs in the United States by spending, with adalimumab, etanercept, and infliximab accounting for $13.6 billion, $7.4 billion, and $5.3 billion in total expenditures across all indications, respectively. 2 Despite this growing problem of rising costs of specialty medications, it is difficult to find accurate estimates of the costs of individual drugs. Currently, most estimates of the costs of specialty medications use average wholesale price and wholesale acquisition cost, which are benchmarks reported by manufacturers without significant standardized oversight. These measures do not account for discounts, rebates, and price reductions, all of which are commonplace in the pricing of prescription medications.
To remedy this problem, the US Centers for Medicare & Medicaid Services have developed nationwide surveys of invoice prices for prescription medications from retail community pharmacies to create a new metric, the National Average Drug Acquisition Cost. This new pricing benchmark is representative of the costs of medications to pharmacies and accounts for manufacturer-topharmacy price reductions, which are not disclosed in manufacturer-reported measures. Therefore, this measure provides a more accurate representation of the actual costs of prescription medications.
NADAC data from the Medicaid Pharmacy Pricing database from November 28, 2013, to October 4, 2017, were analyzed for this study. Annual costs of specialty medications (biologic or small molecule therapies) were calculated on the basis of standard on-label approved dosing regimens for plaque psoriasis.
The first-year cost of specialty medications in 2017 for plaque psoriasis per Medicaid patient ranged from $34,213.37 to $91,404.58, whereas the annual cost of maintenance treatment ranged from $34,401.88 to $79,217.30 per patient (Table I) . From 2013 to 2017, the cost of biologic and small molecule medications rose at an annual rate of 9% for ustekinumab, 16% for apremilast, 17% for etanercept, and 18% for adalimumab (Fig 1) . Rates of increase in the cost of psoriasis medications were the same for treatment in the first year and maintenance treatment.
One limitation of NADAC is that it does not account for manufacturer-toepharmacy benefits manager rebates and manufacturer-toehealth plan discounts, yet these also contribute significantly to rising drug costs. Additionally, specialty pharmacies dispense a large portion of biologic medications and may negotiate medication pricing rates different from those of retail pharmacies but were not surveyed for NADAC. Health care spending in the United States is expected to rise 6% annually over the next 7 years, with increasing drug prices implicated as 1 of the primary reasons for this. 3 Specialty drugs in particular contribute disproportionally to overall drug spending in the United States, and this cost is expected to continue increasing on account of increased adoption and rising costs of these drugs. 4 Greater transparency in the pricing of prescription medications will be necessary to combat this growing problem and deliver cost-conscious and cost-effective care.
